Actively Recruiting
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Led by Hackensack Meridian Health · Updated on 2026-02-18
66
Participants Needed
2
Research Sites
211 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.
CONDITIONS
Official Title
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented newly diagnosed multiple myeloma
- At least 25% of patients should be high risk by IMWG or mSMART criteria
- Eligible for transplant
- No more than 1 cycle of prior induction therapy; if 1 cycle, must have measurable disease before starting
- At least 18 years old and able to sign informed consent
- Willing and able to follow study visit schedule and protocol requirements
- Measurable disease defined by specified M-protein or light chain criteria
- ECOG performance status 0, 1, or 2
- Female of childbearing potential must have negative pregnancy tests before and during study and agree to pregnancy monitoring
- Agree to use effective contraception or true abstinence during and for 28 days after treatment
- Male participants must agree to abstinence or condom use during and for 28 days after treatment
- Male participants must agree to avoid sperm donation during and for 28 days after treatment
- All participants must avoid blood donation during and for 28 days after treatment
- Follow all Pregnancy Prevention Program requirements
You will not qualify if you...
- Significant medical conditions, lab abnormalities, or psychiatric illness preventing participation
- Conditions or lab abnormalities placing participant at unacceptable risk
- Conditions affecting data interpretation
- Nonsecretory multiple myeloma
- Plasma cell leukemia or amyloidosis except isolated marrow involvement
- Absolute neutrophil count less than 1000/µL
- Platelet count less than 50,000/µL without transfusion
- Corrected serum calcium greater than 13.5 mg/dL
- Liver enzymes greater than 2.5 times upper limit of normal
- Elevated bilirubin or alkaline phosphatase greater than 1.5 times upper limit
- Serious renal impairment (creatinine clearance less than 30 mL/min) or dialysis
- Peripheral neuropathy grade 2 or higher
- Gastrointestinal disease affecting iberdomide absorption
- Prior malignancies except certain noninvasive skin or cervical cancers unless disease-free for 3 years
- History of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, or pomalidomide
- Contraindications to other study treatments
- Recent plasmapheresis, major surgery, radiation (except local for bone lesions), or systemic myeloma therapy within 14 days
- Recent investigational agent within 28 days or 5 half-lives
- Active or recent serious cardiac conditions
- Recent use of immunosuppressive medications except certain exceptions
- Use of strong CYP3A4/5 inhibitors or inducers within two weeks prior to dosing
- Known HIV infection or uncontrolled viral hepatitis
- Unable or unwilling to undergo required thromboembolism prevention
- Pregnant, nursing, or unwilling to comply with contraceptive requirements
- Left ventricular ejection fraction less than 40%
- Prior use of iberdomide
- Uncontrolled hypertension or diabetes within 14 days prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States, 20007
Actively Recruiting
2
John Theurer Cancer Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
Research Team
P
Palka Anand
CONTACT
K
Kristin Ivanovski
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here